Harvard Bioscience Inc. has announced its financial results for the third quarter of 2026, showcasing an 8% increase in revenue year-over-year. The company reported revenues of $22.2 million for the quarter, up from $20.6 million in the same period last year. This growth reflects the company's strong performance and ongoing demand for its products in the laboratory analytical instruments sector.

John Duke, President and Chief Executive Officer of Harvard Bioscience, expressed optimism about the company's trajectory. He stated, "We delivered our second consecutive quarter of strong year-over-year growth with an 8% topline increase in the third quarter. We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products." Duke also noted that the company's revamped sales and marketing teams are yielding positive results.

Harvard Bioscience, Inc. is a leading developer and manufacturer in the laboratory analytical instruments industry, focusing on technologies that support life sciences research. The company trades under the ticker HBIO on the Nasdaq exchange. Its recent filings include a 10-Q and multiple 8-Ks, indicating active engagement with investors and stakeholders.

The latest filing, dated November 10, 2026, reveals that Harvard Bioscience's gross profit for the third quarter was $12.3 million, with a gross margin of 55.4%. The company also reported a net loss of $(2.6) million for the quarter, compared to a net loss of $(1.2) million in Q3 2025. Adjusted EBITDA for the quarter was $1.8 million, down from $2.0 million in the same period last year.

For the nine months ended September 30, 2026, Harvard Bioscience reported revenues of $65.7 million, compared to $62.8 million for the same period in 2025. The company reaffirmed its full-year revenue guidance of 3%-5% growth, indicating confidence in its operational strategies and market demand.

Looking ahead, Harvard Bioscience expects continued momentum in sales, particularly within its Cellular & Molecular Technology (CMT) and New Product Innovation (NPI) platforms. The company anticipates revenue for the fourth quarter to be between $23.7 million and $25.5 million, with an adjusted gross margin between 59% and 61%.

As Harvard Bioscience continues to navigate the competitive landscape of laboratory analytical instruments, it remains to be seen how its competitors will respond to its positive performance. The company’s focus on innovation and market expansion may set a benchmark for others in the industry.

The filing does not specify what happens next, but the company is scheduled to host a conference call to discuss these results further.